Mobile Element Insertion Detection via Hybridization Capture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and quantifying Mobile Element Insertions (MEIs) in the human genome lack sensitivity and specificity, leading to inaccurate representation of MEI activity in disease contexts, particularly in cancer and aging, due to biases in sample preparation and analysis.
Innovation Solution
Developed methods involve targeted sequencing and the use of redundant primers and natural labels to confirm and quantify MEI insertion events, avoiding amplification biases and chimeric molecule formation, allowing for precise measurement of MEI levels and their impact on gene function over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If conventional amplification methods are used to detect MEI insertion events, then sensitivity of detection is improved, but amplification biases and chimeric molecule formation occur leading to reduced measurement precision
Solution Approach 1:
The patent introduces an intermediary step of target enrichment using hybridization capture technology before amplification. This intermediary process uses biotinylated RNA or DNA probes to specifically bind and enrich MEI-containing DNA fragments, allowing subsequent amplification to occur only on enriched targets rather than whole genome, thereby reducing amplification biases while maintaining detection sensitivity
Solution Approach 2:
The patent extracts and isolates only the relevant MEI insertion sequences from the complex genomic background using hybridization capture. By taking out specifically the MEI-containing fragments through probe hybridization and streptavidin bead capture, the method enables focused amplification and sequencing of only the regions of interest, eliminating background noise and reducing chimeric molecule formation
2Area of stationary object
If whole genome sequencing is performed to detect MEIs, then comprehensive coverage is achieved, but cost and complexity increase significantly
Solution Approach 1:
The patent segments the genome analysis process into two distinct phases: (1) hybridization capture to enrich and isolate MEI-containing fragments, and (2) targeted amplification and sequencing of only those enriched fragments. This segmentation allows comprehensive MEI detection without requiring whole genome sequencing, thereby reducing cost and complexity while maintaining effective coverage of MEI regions
Solution Approach 2:
The patent applies partial action by performing amplification and sequencing only on the MEI-enriched fraction of the genome rather than the entire genome. This partial approach focuses resources on the specific regions containing MEI insertions, achieving sufficient coverage for accurate MEI detection without the excessive cost and complexity of complete whole genome sequencing
3Difficulty of detecting and measuring
If standard PCR amplification is used to increase MEI signal, then detection sensitivity is improved, but amplification biases lead to inaccurate MEI level representation
Solution Approach 1:
The patent introduces hybridization capture as an intermediary enrichment step before amplification. This intermediary process uses complementary probes to specifically bind and concentrate MEI-containing fragments, ensuring that subsequent PCR amplification starts with a pre-enriched, representative pool of targets. This reduces amplification biases by ensuring all MEI variants are equally enriched before amplification begins
Solution Approach 2:
The patent performs preliminary enrichment of MEI fragments through hybridization capture before the amplification step. By pre-concentrating and purifying the MEI-containing DNA fragments in advance, the method ensures that amplification operates on a balanced, representative sample pool, thereby maintaining accurate relative abundance information while achieving the necessary signal sensitivity
Data Source
Figure 1
Figure 2
AI summary
Methods and compositions related to the use of Mobile Element Insertions and their adjacent genomic sequences. Methods using MEIs as markers for cellular proliferation, as targets for pharmaceuticals, as markers for tissue fingerprinting and in related methods and compositions are disclosed herein. Methods and compositions relate to the detection, treatment and ongoing monitoring of cell proliferation events, cancer, and deleterious effects of mobile elements in aging, and to the selection, use and monitoring of the success of treatment regimens to address these conditions.